LP 44

Discontinued Product

LP 44 (Cat. No. 2534) has been withdrawn from sale for commercial reasons.
Cat.No. 2534 - LP 44 | C27H37N3OS.HCl | CAS No. 824958-12-5
Description: High affinity 5-HT7 agonist
Chemical Name: 4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydro-1-naphthalenyl)-1-piperazinehexanamide hydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (2)
Reviews
Literature

Biological Activity

High affinity 5-HT7 receptor agonist (Ki = 0.22 nM) that displays selectivity over 5-HT1A and 5-HT2A receptors (200- and > 1000-fold respectively). Induces relaxation of substance P-stimulated guinea pig ileum (EC50 = 2.56 μM).

Licensing Information

Sold under license from the University of Bari

Technical Data

M. Wt 488.13
Formula C27H37N3OS.HCl
Storage Desiccate at RT
Purity ≥98% (HPLC)
CAS Number 824958-12-5
PubChem ID 11225543
InChI Key DWGKCWWWKHCVDH-UHFFFAOYSA-N
Smiles O=C(CCCCCN3CCN(C4=C(SC)C=CC=C4)CC3)NC1CCCC2=C1C=CC=C2.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

Product Datasheets

Certificate of Analysis / Product Datasheet
Select another batch:

References

References are publications that support the biological activity of the product.

Leopoldo et al (2004) Structure-affinity relationship study on N-(1,2,3,4-tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinealkylamides, a new class of 5-hydroxytryptamine7 receptor agents. J.Med.Chem. 47 6616 PMID: 15588097

View Related Products by Target

View Related Products by Product Action

View all 5-HT7 Receptor Agonists

Keywords: LP 44, LP 44 supplier, High, affinity, 5-HT7, agonists, Serotonin, Receptors, 5-Hydroxytryptamine, LP44, 2534, Tocris Bioscience

2 Citations for LP 44

Citations are publications that use Tocris products. Selected citations for LP 44 include:

Watts et al (2015) 5-HT is a potent relaxant in rat superior mesenteric veins. Mol Med 3 e00103 PMID: 25692021

Murray et al (2011) Polysynaptic excitatory postsynaptic potentials that trigger spasms after spinal cord injury in rats are inhibited by 5-HT1B and 5-HT1F receptors. J Neurophysiol 106 925 PMID: 21653728


Reviews for LP 44

There are currently no reviews for this product. Be the first to review LP 44 and earn rewards!

Have you used LP 44?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


GPCR

GPCR Product Listing

A collection of over 450 products for G protein-coupled receptors, the listing includes research tools for the study of:

  • Rhodopsin-like Receptors
  • Secretin-like Receptors
  • Glutamate Receptors
  • Frizzled Receptors
  • GPCR Signaling
5-HT Receptors

5-HT Receptors Scientific Review

Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.

Cardiovascular

Cardiovascular Poster

Cardiovascular disease remains one of the major causes of morbidity and mortality in the Western world and therefore this therapeutic area continues to be of great interest to researchers. This poster highlights the key GPCRs regulating vascular reactivity.

Depression

Depression Poster

Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.